Levent KILIÇ,
Muhammet ÇINAR,
Aşkın ATEŞ,
Ömer KARADAĞ,
Ali İhsan ERTENLİ,
Ali ŞAHİN,
Hüseyin Ediz DALKILIÇ,
Cemal BES,
Ayşe Bahar KELEŞOĞLU DİNÇER,
Veli YAZISIZ,
Orhan KÜÇÜKŞAHİN,
Ender TERZİOĞLU,
Nilüfer ALPAY KANITEZ,
Hakan EMMUNGİL,
Yavuz PEHLİVAN,
Gezmiş KİMYON,
Sedat KİRAZ,
Rıdvan MERCAN,
Burc
3917
Methodology of a new inflammatory arthritis registry: TReasure
Methodology of a new inflammatory arthritis registry: TReasure
Background/aim: The TReasure registry, created in 2017, is an observational multicenter cohort that includes inflammatory arthritispatients. This article reviews the methodology and objectives of the TReasure registry established to collect data from rheumatoidarthritis (RA) and spondyloarthritis (SpA) patients.Methodology: Fifteen rheumatology centers in Turkey will contribute data to the TReasure database. The actual proprietor of thedatabase is the Hacettepe Rheumatology Association (HRD) and Hacettepe Financial Enterprises. Pharmaceutical companies thatoperate in Turkey (in alphabetical or er), Abbvie, Amgen, BMS, Celltrion Healthcare, Novartis, Pfizer, Roche, and UCB, support theTReasure registry. TReasure is a web-based database to which users connect through a URL (https://www.trials-network.org/treasure)with their unique identifier and passwords provided for data entry and access. TReasure records demographic and clinical features,comorbidities, radiology and laboratory results, measures of disease activity, and treatment data.Discussion: TReasure will provide us with various types of data, such as a cross-sectional view of the current nationwide status of thepatients currently receiving these treatments, and retrospective data as much as allowed by the participating centers’ records. Finally, ahigh-quality prospective dataset will be built over the ensuing years from patients with a new diagnosis of RA or SpA.
___
- Askling J, Baecklund E, Granath F, Geborek P, Fored M, Backlin
C, Bertilsson L, Cöster L, Jacobsson LT, Lindblad S et al. Antitumour necrosis factor therapy in rheumatoid arthritis and risk
of malignant lymphomas: relative risks and time trends in the
Swedish Biologics Register. Ann Rheum Dis 2009; 68: 648-653.
- Lapadula G, Ferraccioli G, Ferri C, Punzi L, Trotta F. GISEA: An
Italian biological agents registry in rheumatology. Reumatismo
2011; 63: 155-164.
- Mariette X, Gottenberg JE, Ravaud P, Combe B. Registries in
rheumatoid arthritis and autoimmune diseases: data from the
French registries. Rheumatology (Oxford) 2011; 50: 222-229.
- Strangfeld A, Eveslage M, Schneider M, Bergerhausen HJ,
Klopsch T, Zink A, Listing J. Treatment benefit or survival of
the fittest: what drives the time-dependent decrease in serious
infection rates under TNF inhibition and what does this imply
for the individual patient? Ann Rheum Dis 2011; 70: 1914-
1920.
- de la Vega M, da Silveira de Carvalho HM, Ventura Rios
L, Goycochea Robles MV, Casado GC. The importance of
rheumatology biologic registries in Latin America. Rheumatol
Int 2013; 33: 827-835.
- Ibfelt EH, Jensen DV, Hetland ML. The Danish nationwide
clinical register for patients with rheumatoid arthritis:
DANBIO. Clin Epidemiol 2016; 8: 737-742.
- Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon
WG, Watson KD; BSRBR Control Centre Consortium,
Symmons DP, Hyrich KL. Risk of lymphoma in patients
exposed to antitumour necrosis factor therapy: results from
the British Society for Rheumatology Biologics Register for
Rheumatoid Arthritis. Ann Rheum Dis 2017; 76: 497-503.
- Strand V, Miller P, Williams SA, Saunders K, Grant S, Kremer
J. Discontinuation of biologic therapy in rheumatoid arthritis:
analysis from the Corrona RA Registry. Rheumatol Ther 2017;
4: 489-502.
- Ruderman EM. Overview of safety of non-biologic and
biologic DMARDs. Rheumatology (Oxford) 2012; 51 (Suppl.
6): vi37-43.
- Erden A, Kılıç L, Karadağ Ö, Akdoğan A, Bilgen ŞA, Kıraz
S, Ertenli İ, Kalyoncu U. Ankilozan spondilit hastalarında
golimumab kullanımı: HÜR-BİO/Spondiloartrit gerçek yaşam
deneyimi. RAED Dergisi 2015; 7: 6-9 (in Turkish).
- Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF,
Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al.
The American Rheumatism Association 1987 revised criteria
for the classification of rheumatoid arthritis. Arthritis Rheum
1988; 31: 315-324.
- Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham
CO 3rd, Birnbaum NS, Burmester GR, Bykerk VP, Cohen
MD et al. 2010 Rheumatoid arthritis classification criteria: an
American College of Rheumatology/European League Against
Rheumatism collaborative initiative. Arthritis Rheum 2010; 62:
2569-2581.
- van der Linden S, Valkenburg HA, Cats A. Evaluation of
diagnostic criteria for ankylosing spondylitis. A proposal for
modification of the New York criteria. Arthritis Rheum 1984;
27: 361-368.
- Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc
N, Brandt J, Braun J, Chou CT, Collantes-Estevez E, Dougados
M et al. The development of Assessment of SpondyloArthritis
International Society classification criteria for axial
spondyloarthritis (Part II): validation and final selection. Ann
Rheum Dis 2009; 68: 777-783.
- Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt
J, Chou CT, Dougados M, Huang F, Gu J, Kirazli Y et al.
The Assessment of SpondyloArthritis International Society
classification criteria for peripheral spondyloarthritis and for
spondyloarthritis in general. Ann Rheum Dis 2011; 70: 25-31.
- Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease
P, Mielants H. Classification criteria for psoriatic arthritis:
development of new criteria from a large international study.
Arthritis Rheum 2006; 54: 2665-2673.
- Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new
method of classifying prognostic comorbidity in longitudinal
studies: development and validation. J Chronic Dis 1987; 40:
373-383.
- Borg GA. Psychophysical bases of perceived exertion. Med Sci
Sports Exerc 1982; 14: 377-381.
- Calin A, Porta J, Fries JF, Schurman DJ. Clinical history as a
screening test for ankylosing spondylitis. JAMA 1977; 237:
2613-2614.
- Rudwaleit M, Metter A, Listing J, Sieper J, Braun J. Inflammatory
back pain in ankylosing spondylitis: a reassessment of the
clinical history for application as classification and diagnostic
criteria. Arthritis Rheum 2006; 54: 569-578.
- Sieper J, van der Heijde D, Landewé R, Brandt J, Burgos-Vagas
R, Collantes-Estevez E, Dijkmans B, Dougados M, Khan
MA, Leirisalo-Repo M et al. New criteria for inflammatory
back pain in patients with chronic back pain: a real patient
exercise by experts from the Assessment of SpondyloArthritis
International Society (ASAS). Ann Rheum Dis 2009; 68: 784-
788.
- Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic
arthritis: assessment of existing measures and development of
an instrument specific to psoriatic arthritis. Arthritis Rheum
2008; 59: 686-691.
- Bruce B, Fries JF. The Stanford Health Assessment
Questionnaire: a review of its history, issues, progress, and
documentation. J Rheumatol 2003; 30: 167-178.
- Prevoo ML, van’t Hof MA, Kuper HH, van Leeuwen MA, van
de Putte LB, van Riel PL. Modified disease activity scores that
include twenty-eight-joint counts. Development and validation
in a prospective longitudinal study of patients with rheumatoid
arthritis. Arthritis Rheum 1995; 38: 44-48.
- Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold
K, Smolen JS. Acute phase reactants add little to composite
disease activity indices for rheumatoid arthritis: validation of
a clinical activity score. Arthritis Res Ther 2005; 7: 796-806.
- Calin A, Nakache JP, Gueguen A, Zeidler H, Mielants
H, Dougados M. Defining disease activity in ankylosing
spondylitis: is a combination of variables (Bath Ankylosing
Spondylitis Disease Activity Index) an appropriate instrument?
Rheumatology (Oxford) 1999; 38: 878-882.
- Calin A, Garrett S, Whitelock H, Kennedy LG, O’Hea J,
Mallorie P, Jenkinson T. A new approach to defining functional
ability in ankylosing spondylitis: the development of the Bath
Ankylosing Spondylitis Functional Index. J Rheumatol 1994;
21: 2281-2285.
- Lukas C, Landewé R, Sieper J, Dougados M, Davis J, Braun
J, van der Linden S, van der Heijde D; Assessment of
SpondyloArthritis International Society. Development of an
ASAS-endorsed disease activity score (ASDAS) in patients
with ankylosing spondylitis. Ann Rheum Dis 2009; 68: 18-24.
- Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring
health-related quality of life in rheumatoid arthritis: validity,
responsiveness and reliability of EuroQol (EQ-5D). Br J
Rheumatol 1997; 36: 551-559.
- Kiltz U, van der Heijde D, Boonen A, Cieza A, Stucki G,
Khan MA, Maksymowych WP, Marzo-Ortega H, Reveille J,
Stebbings S et al. Development of a health index in patients
with ankylosing spondylitis (ASAS HI): final result of a global
initiative based on the ICF guided by ASAS. Ann Rheum Dis
2015; 74: 830-835.
- Salaffi F, Di Carlo M, Carotti M, Farah S, Gutierrez M. The
Psoriatic Arthritis Impact of Disease 12-item questionnaire:
equivalence, reliability, validity, and feasibility of the touchscreen administration versus the paper-and-pencil version.
Ther Clin Risk Manag 2016; 12: 631-642.
- Fredriksson T, Pettersson U. Severe psoriasis--oral therapy
with a new retinoid. Dermatologica 1978; 157: 238-244.